Inagaki et al. [37], studied CD68+CD163− (M1) and CD68+CD163+ (M2) macrophages in four different CRC tumor regions (invasive front, tumor center, lateral periphery of the tumor, and healthy mucosa adjacent to the tumor) and showed a dynamic increase in M2 TAM number and M2/M1 ratio at the invasive front during cancer progression [37]. This evidence concerns the gene CD163 and cancer.